Wuxi Apptec (603259:SSE) written Q&A, August 27, 2026 transcript

Transcript, summary, guidance, and what analysts pressed on from the Wuxi Apptec call on August 27, 2026.

FreeSee Wuxi Apptec's financials in GloomOpen in browser →Jump to the transcript
Held
August 27, 2026
Tone
Positive0.48
Words
2,648
2026 TIDES growth
about 45%full-year guidance
2026 capital expenditure
7.5-8.5 billion yuancited by investor
Quality audits and inspections
465no serious findings
Information security audits
21no serious findings
Small-molecule D&M pipeline
3,731 molecules
New commercial and Phase III projects
15added in first half

Summary

Management framed the raised outlook as demand-led pipeline conversion, while emphasizing execution, capacity readiness and resilience amid geopolitical and currency headwinds.

  • 45%TIDES guidance remained about 45% growth despite a slower first-half pace, which management attributed to a larger revenue base.
  • New capacity was justified by pipeline depth and rapid quarterly validation, not quantified utilization or depreciation assumptions.
  • Management acknowledged actual order cancellations and project suspensions from 1260H misidentification, while describing the affected customer count as very small.

Guidance

  • 60.5B2026 revenue guidance RMB 58.5–60.5 billion, raised from RMB 51.3–53.0 billion
  • 45%2026 TIDES revenue growth about 45%
  • 8.5B2026 capital expenditure RMB 7.5–8.5 billion, cited in investor question; not restated by management

What analysts pressed on

  • 01TIDES growth durability: management cited about 45% full-year growth and said GLP-1 expands peptide market demand.
  • 02Gross-margin durability and FX hedging: CFO cited partial hedging and efficiency gains, but gave no margin or hedge detail.
  • 03Compliance and data security: management cited completed audits and certifications, but did not address specific lost-customer cases beyond 1260H.
  • 04U.S. customer concentration and geopolitical risk: management acknowledged some cancellations and suspensions, but did not quantify order shifts to Europe or India.
  • 05Capacity spending and pipeline digestion: management cited 3,731 small-molecule D&M molecules and faster capacity release, but did not quantify utilization or returns.
  • 06Cash conversion and receivables: CFO attributed divergence to project delivery timing and said collections remained healthy, without discussing customer-specific payment terms.

Notable disclosures

  • 465 global customer, regulator and third-party quality audits and inspections and 21 information-security audits were completed with no serious findings.
  • 20 major operating bases had ISO/IEC 27001 certification, covering all major China operating bases.
  • 3,731 small-molecule D&M pipeline molecules and 15 additional commercial or Phase III projects were cited as evidence of later-stage conversion.
  • Management acknowledged geopolitical disruptions had caused real harm and that a very small number of customers cancelled orders or suspended projects over 1260H misidentification.

Risks raised

  • U.S. dollar depreciation and rising local costs were identified as external profit pressures, partly offset by hedging and operating efficiencies.
  • 1260H-list misidentification caused some customers to cancel orders or suspend projects; management did not quantify the impact.
  • Revenue concentration remained exposed to the U.S.: American customers represented 77.1% of first-half revenue, as cited by the investor.
  • Higher receivables and slower operating-cash-flow growth were attributed to project delivery timing, leaving collection timing a watchpoint.

Tone: Positive 0.48

Management expressed confidence in raised guidance and pipeline conversion, but acknowledged geopolitical order disruption, FX pressure and unresolved cash-timing concerns.

Who spoke

Company

  • Minzhang ChenExecutive Director, Co-Chief Executive Officer, WUXI APPTEC
  • Ming ShiChief Financial Officer, WUXI APPTEC
  • Hao WuHead of Global Legal Affairs, WUXI APPTEC
  • Han MinBoard Secretary, WUXI APPTEC
  • Qing YangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC
  • Wei YuChief Independent Director, WUXI APPTEC

Full transcript

Analyst questions are marked with a bar. Timestamps are into the recording.

Prepared remarks

ModeratorSSE Roadshow Center

Ladies and gentlemen, investors and netizens, hello! Welcome to WuXi AppTec's Semi-Annual Results Presentation for 2026. This activity is sponsored by Wuxi WuXi AppTec New Drug Development Co., Ltd. and supported by the network platform provided by Shanghai Stock Exchange Information Network Co., Ltd. Thank you for your attention and participation. On August 4, Wuxi Yaoming Kangde New Drug Development Co., Ltd. published the Semi-annual Report for 2026. Investors can log on the website of Shanghai Stock Exchange (https://www.sse.com.cn/) or this platform (https://roadshow.sseinfo.com/).

View related announcements. In order to facilitate investors to have a more comprehensive and in-depth understanding of the company's operating results and financial situation in the first half of 2026, the company decided to hold a semi-annual performance presentation of Yaoming Kangde in 2026. In today's event, the main members of the management of Yaoming Kangde visited the Shanghai Roadshow Center and will communicate with investors. Everyone is welcome to participate actively.

Questions and answers

Investor

Hello, Dr. Chen. The semi-annual report shows that the revenue of TIDES (polypeptide and oligonucleotide) business in the first half of the year was 7.26 billion yuan, an increase of 44.3% over the same period last year, but the growth rate slowed down significantly compared with 96% in the whole year of 2025. With the intensification of competition in the market of weight-loss drugs such as GLP-1, the company expects TIDES to grow by about 45% in the whole year.

How does the management view the decline of this growth rate? Does this mean that the dividend period of the polypeptide CDMO track is weakening?

Minzhang ChenExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

The company believes that after the rapid growth in the past few years, the revenue of TIDES business has exceeded 10 billion yuan in the past 25 years. At this scale, the company still raised its revenue guidance for TIDES business to a strong growth of about 45% this year. GLP-1 is a revolutionary product, which is expected to reshape the disease map of future generations. The market demand is huge, and it opens up the market space for the exploration of polypeptide drugs.

As an integrated CRDMO service platform, we are also continuing to build new polypeptide production capacity. We will continue to give full play to the capabilities and scale advantages of CRDMO integrated service platform to better meet the growing needs of customers with efficient and extreme services.

Investor

In the first half of the year, the overall gross profit margin rose sharply to 53.91%, but the company also admitted that overseas revenue exceeded 70%, and exchange rate fluctuations would erode profits. In the current environment of fluctuations in the US dollar exchange rate, what specific financial hedging tools have the company adopted to lock in profits? In addition, the gross profit margin of testing business rebounded sharply from 29.26% last year to 37.95%. Is this repair structural or phased?

Ming ShiChief Financial Officer, WUXI APPTEC

The company believes that objectively, the company is indeed facing the adverse impact of the macro environment such as the depreciation of the US dollar and the rise in local costs. However, with the continuous promotion of high-quality customers from the front end to the back end, more and more pipelines have entered the later stage and commercial production. The company has efficiently managed the new production capacity climbing, gradually realized the scale benefit, and continuously improved the production and operation efficiency.

At the same time, the company improved its financial management ability and locked in part of the exchange rate fluctuation risk through effective hedging. These measures have effectively hedged the negative external impact. Throughout the year, we are confident that we will maintain a stable and resilient net interest rate.

Investor

In the current complex international situation, some overseas customers are highly sensitive to data security. How does the company prove the effectiveness of its data barrier to customers at the global legal compliance level? Are there any actual cases of loss of large customers or delay of orders due to compliance review?

Hao WuHead of Global Legal Affairs, WUXI APPTEC

The company believes that since its establishment more than 20 years ago, the company has adhered to the principle of customer first, adhered to the highest quality system and compliance standards in the industry, and fulfilled its firm commitment to protect the intellectual property rights of customers. In the first half of 2026, the company successfully completed 465 quality audits and inspections from global customers, regulators and independent third parties, and 21 information security audits from global customers, with no serious findings.

The company's 20 major operating bases have been certified by ISO/IEC 27001 Information Security Management System, covering all major operating bases in China. Intellectual property is the lifeblood of both the company and its customers. Honesty and dedication are the foundation of the company, and we always maintain "zero tolerance" for any infringement. This is not only the core value of WuXi AppTec, but also our highest responsibility and commitment.

We are very grateful to thousands of customers around the world for their continued trust in us, thanks to the continuous progress of the industry and the continued success of our customers, so that we can continue to deliver satisfactory performance to investors.

Investor

Hello, Ms. Han. The company has substantially raised its full-year 2026 revenue guidance to 58.5–60.5 billion yuan (from 51.3–53.0 billion yuan). Given the uncertainty in the macro environment in the second half of the year, what is the core basis for management's confidence in making such an aggressive increase? Does this mean that several major commercial projects will see a concentrated ramp-up in the second half of the year?

Han MinBoard Secretary, WUXI APPTEC

The company believes that thanks to the remarkable success of many customer products, customers'demand for our orders and delivery speed exceeded the expectations of the guidance at the beginning of the year. This also proves once again the advantages of the company's unique CRDMO business model, as well as the team's excellent management and execution capabilities.

Investor

Hello, Mr. Chen, will your company develop its domestic business in the short term?

Minzhang ChenExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

The company believes that the company has always been committed to serving global customers and is a trustworthy partner and important contributor to the global pharmaceutical and life sciences industry. The company's CRDMO enabling platform carries the R & D and innovation projects of thousands of customers from more than 30 countries around the world, bringing more new and good drugs to patients around the world. The revenue disclosed by the company is collected according to the location of the customer's headquarters, while the actual daily business needs come from all over the world.

Investor

The company announced that it would raise its capital expenditure to 7.5-8.5 billion yuan in 2026 and start the construction of a new base in Changzhou ahead of schedule. With the chemical business accounting for more than 86%, will the expansion of such heavy assets aggravate the depreciation pressure of the company? How to ensure that new production capacity can be effectively digested by current orders in hand (66.43 billion yuan) and new pipelines in the future?

Minzhang ChenExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

The Company believes that under the unique CRDMO business model of the Company, the pipeline will be continuously and efficiently transformed, and the high-quality and high-value molecules will be continuously drained and steadily promoted to the later stage. CRDMO business model also brings more foresight to the company, so that we can advance the layout of production capacity and capacity, faster and better to meet customer needs.

At present, the company's small molecule D & M pipeline has reached 3,731 molecules, and the number of commercial and clinical phase III projects increased by 15 in the first half of the year. This is the natural realization of the continuous and efficient transformation of the company's high-quality pipelines, and further enhances the sustainability and certainty of our business.

In order to better meet the growing customer demand, we will continue to accelerate the global layout and capacity and capacity building, but also thanks to the efficient implementation of the team, so that these new capacity can be quickly verified and released quarter by quarter.

Investor

In the first half of the year, the company added 15 new commercial and clinical phase III projects, with a good rhythm. However, under the background that the investment and financing environment of innovative drugs in the world is still fluctuating, can number of molecules transformed from the front-end funnel to the later stage continue to grow at a high rate? How can company help small and medium-sized Biotech customers overcome the capital bottleneck in the late clinical stage to ensure the sustained growth of the company's back-end D & M business?

Qing YangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

The company believes that in the past few quarters, the R & D and financing situation in the early stage of the global industry is gradually recovering. Especially in new molecular species and hot areas, the market demand has maintained a good growth trend. In the current complex environment, customers also pay more attention to high-quality and differentiated services.

Our unique CRDMO business model enables the company's pipelines to be continuously and efficiently transformed, continuously draining high-quality molecules to the later stage, and most of the new Phase III and commercial projects in the first half of the year are also the realization of our molecular strategy. In terms of price strategy, we should focus on differentiation ability and high-quality customers. With excellent service quality and globally recognized delivery standards, we continue to enable customers to cooperate globally, accelerate new drug innovation, and continue to attract high-quality customers.

Investor

The company has continuously received the highest "AAA" rating from MSCI ESG, but in the context of the 1260H list review by the U.S. Department of Defense, is the company's compliance governance system adequate to cope with the rigorous review of overseas regulation? Is there a special supervision mechanism for overseas geopolitical risks at the level of independent directors to prevent irreversible damage to shareholders'rights and interests caused by systemic risks?

Wei YuChief Independent Director, WUXI APPTEC

As for the risks brought by geopolitics, independent directors have regarded it as a very important core issue. At each meeting of the Audit Committee of the Board of Directors, we will focus on reviewing and assessing the impact of geopolitics on the company's operations, and closely monitor and discuss the company's global layout planning and compliance governance. We believe that the company's compliance governance system is not static, but has been making forward-looking adjustments and strengthening with the changes in the global geopolitical environment.

At the same time, we also strongly agree with and firmly support the current global layout strategy adopted by the management, the continuous improvement of the compliance governance system and the coordinated global operation strategy.

Investor

Hello, Dr. Yang. In the first half of the year, the revenue from American customers reached 22.28 billion yuan, accounting for 77.1%, and increased by 61.5% year on year. Under the shadow of external geopolitical risks such as the Biosafety Act (BIOSECURE Act) and the 1260H list, does the "counter-trend overweight" order of American customers have long-term stability? Has the company observed any signs that some U.S. customers are beginning to shift some of their orders to Europe or India?

Qing YangExecutive Director, Co-Chief Executive Officer, WUXI APPTEC

The company thinks: The income cent area that we disclose, it is to be done according to client headquarters seat collect. The actual daily needs of business come from all over the world. The company is committed to serving customers worldwide, no matter where they come from. The geopolitical disruptions of the past few years have hurt us in real terms, and without these impacts, we can focus more on our business and operations, empower more customers and benefit patients.

The wrong identification of the 1260H list has caused a very small number of our customers to cancel orders or suspend projects, and the harm and interference to us are objective. Despite the challenges and interference of the external environment, the company has honed the "formula" of "extreme quality, extreme speed and high cost efficiency" in adversity. The company will always adhere to the principle of "doing the right thing, doing the right thing", empower global innovators, and realize the great vision of "making the world without difficult medicine and incurable diseases" as soon as possible.

Han MinBoard Secretary, WUXI APPTEC

Due to time constraints, the semi-annual results presentation of WuXi AppTec for 2026 has ended. I am very glad to discuss and communicate with you on the company's industry situation, business situation and other aspects. I also sincerely thank all investors for their warm and friendly exchanges and their continuous attention and ardent expectations for WuXi AppTec! After the meeting, investors are welcome to further communicate with us through diversified ways such as investor relations telephone, e-mail and SSE e-interaction.

Investor

Hello, Dr. Yu. The company recently sold a 4.23% stake in Yaoming United for about HK $3.92 billion, which is expected to contribute a pre-tax profit of HK $3.143 billion. As an independent director, how do you assess the impact of this reduction on the company's long-term strategic synergy? Should this huge non-recurring income be more directly returned to the majority of small and medium shareholders through special dividends or repurchase and cancellation?

Wei YuChief Independent Director, WUXI APPTEC

The cash proceeds from the sale of the above stock assets will be used to continue to focus on the main business, accelerate the construction of global production capacity and capacity, attract and retain outstanding talents, and continue to strengthen the company's unique integrated CRDMO business model, so as to effectively meet the growing and changing needs of global customers and patients. At the same time, we will further optimize the company's capital structure and enhance shareholder returns.

Investor

Hello, General Manager Shi. In the first half of the year, the net profit deducted from non-attributable parent increased by 89.39%, but the growth rate of net operating cash flow (9.699 billion yuan) (30.52%) was obviously backward, and the accounts receivable increased by 43.95% compared with the beginning of the year. Is this phenomenon of "high book profit but slow cash withdrawal" due to the extension of the account period of large customers or the decline of bargaining power caused by industry competition?

Ming ShiChief Financial Officer, WUXI APPTEC

The Company believes that under the unique CRDMO business model of the Company, the pipeline has been continuously and efficiently transformed, and high-quality and high-value molecules have been continuously drained and steadily promoted to the later stage, which has brought a large number of high-quality molecules and commercial projects to the Company. At the same time, the company has been adopting strict and effective credit management. Therefore, the company continued to maintain a healthy level of collection, and the turnover rate of accounts receivable further increased in the first half of this year compared with the same period last year.

As for the periodic growth difference between cash flow, accounts receivable and profits you mentioned, it is mainly due to the different delivery rhythm of different projects in a specific quarter. Due to strong demand across businesses and a significant increase in deliveries, there is a natural timing difference between revenue recognition and eventual collection.

ModeratorSSE Roadshow Center

Dear investors and netizens, the semi-annual performance presentation of WuXi AppTec 2026 is drawing to a close. We invite guests from listed companies to make concluding remarks.

ModeratorSSE Roadshow Center

This is the successful conclusion of the semi-annual performance presentation of WuXi AppTec 2026. Thank you for the active participation of investors and netizens. If you have further questions, you can keep communicating with the company through the e interactive platform of Shanghai Stock Exchange. Thank you!

Other Wuxi Apptec earnings calls

  • Q2 2026 earnings call

    Management framed growth as increasingly supported by later-stage molecule progression, rising capacity utilization and operating efficiency.

    Aug 28, 2026Confident0.82
  • written Q&A, April 12, 2026

    Management framed growth around CRDMO capacity expansion and operational efficiency, while offering little quantified detail on pricing, capital allocation or customer concentration.

    Apr 13, 2026Mildly positive0.35
  • written Q&A, November 11, 2025

    Management framed durable CRDMO demand and capacity expansion as the growth engine, while emphasizing policy uncertainty and declining to quantify near-term peptide ramp or pricing effects.

    Nov 12, 2025Mildly positive0.35
  • written Q&A, August 28, 2025

    Management framed the call around strong demand and execution, raising its full-year outlook while balancing shareholder returns with global capacity investment.

    Aug 29, 2025Confident0.75

All Wuxi Apptec transcripts

About this transcript

The call was held in another language and translated. The summary, guidance, analyst focus, and tone are automated and should be checked against the call before being relied on. Names and figures can be misheard. Listen to the replay.